New molecular targets in bone metastases


a Medical Oncology Dept, University Campus Bio-Medico, Rome, Italy
b Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
c Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari, Italy
d Microbiology and Virology Dept, University Campus Bio-Medico, Rome, Italy
e Section of Medical Oncology, Department of Surgical and Oncological Sciences, Università degli Studi di Palermo, Palermo, Italy

ARTICLE INFO

Keywords:
Molecular targets
Bone metastases

SUMMARY

Bone metastases have a major impact on morbidity and mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as “vicious circle”, a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results from those in the advanced clinical phases are encouraging and underlined the need to design large randomised clinical trials to validate these results in the next future.

Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major clinical impact in improving survival in bone metastatic patients and in preventing disease relapse in adjuvant setting.

© 2010 Elsevier Ltd. All rights reserved.

Introduction: Bone metastases – from the niche to “vicious circle”

Bone metastases are the major cause of morbidity, and ultimately mortality, in cancer patients.1 Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The establishment of bone metastasis is driven by a complex network between cancer cells and the bone microenvironment which is classically referred as “vicious circle”. At the earliest steps, prior to the establishment of the vicious cycle, cancer cells and their associated stromal cells alter the marrow environment and prime it by secreting a magnitude of growth factors and cytokines. Bone marrow-derived hematopoietic progenitors that express vascular endothelial growth factor receptor 1 (VEGFR1+) mobilize in response to the unique pattern of growth factors and chemokines produced by the primary tumor. Their arrival in distant sites acts on the local microenvironment, termed the “premetastatic niche,” which dictate the profile of metastatic spread.2

Importantly, examination of bone marrow metastases identified different determinants which might predict for later distant relapse.

Identifying which of these cells have higher metastatic potential is of major clinical significance and therapeutic approach.

In order to form bone metastasis, cancer cells first have to metastasize to the bone marrow which is mainly composed of hematopoietic stem cells (HSCs) residing in two different biological structures known as osteoblastic and vascular niches.

The “osteoblastic niche” is mainly formed by osteoblasts lining at endosteal bone surface and providing a quiescent environment for HSCs maintenance and expansion into different hematopoietic lineages.

Whereas, the vascular niche, identified in association with fenestrated endothelium of sinusoids, drives HSCs transendothelial migration via endothelium-derived factors priming.

Communications between osteoblasts as well as other tumour stromal cells and HSCs are mainly driven via chemoattractive factors such as the stromal-derived factor 1 (SDF-1) on stromal cells and its receptor CXCR4 on HSCs.3

In addition, a cancer-related disruption of the homeostatic RANK-RANKL loop between osteoclasts and osteoblasts occurs. Metastatic prostate carcinomas can secrete high amounts of the RANKL inhibitor osteoprotegerin, thereby attenuating osteoclastic reactions during metastasis.4 Conversely, osteolytic cancer cells can secrete proteases that cleave RANKL into a more active form, thereby activating the osteoclasts.5
PMID: 20820326

RANK/RANKL/OPG pathway

Receptor Activator of nuclear Factor-kB Ligand (RANKL), the Receptor Activator of Nuclear Factor-kB (RANK) and the decoy Receptor Osteoprotergerin (OPG) are members of the TNF and TNF-receptor superfamily able to induce proliferation, differentiation, activation and apoptosis of osteoclastic cells. Bone remodelling is mediated by the interaction among RANKL expressed on the osteoblasts, RANK expressed on the osteoclast surface and OPG, the decoy receptor for RANKL that prevents osteoclast activation. Stromal osteoblast cells support osteoclast differentiation by their ability to secrete IL-6 and RANKL, in response to PTH, 1,25-hydroxyvitamin D3, and PGE2. The interaction between RANK/RANKL begins with the stimulation of RANK by RANKL promoting proliferation, differentiation and survival of osteoclast precursors and activation of mature osteoclasts. OPG, interacting with RANKL, counteracts these effects on osteoclasts.

Thus, RANKL/OPG levels determine bone resorption. For this biological effect, RANK/RANKL/OPG pathway displays a key role in the growth of bone metastases: RANKL activates osteoclast-mediated bone resorption with a consequent release of matrix growth factors, like Tumor Growth Factor-β (TGF-β) and platelet-derived growth factor (PDGF). The release of these factors can further induce the growth of tumor cells establishing a positive feedback mechanism. Moreover, cytokines, chemokines, growth factors and hormones derived from tumor cells upregulate RANKL through parathyroid hormone-related peptide (PTHrP), downregulating OPG. Increasing evidences show a direct role of RANK/RANKL interaction in bone metastases development (“vicious circle”). RANK not only is expressed on osteoclasts, but also on cancer cells. Preclinical evidences on animal models of osteolytic metastases reported targeting RANK/RANKL pathway lead to tumoral growth inhibition with osteolysis reduction.

Denosumab

Denosumab (AMG 162) is a noncytotoxic IgG2 monoclonal antibody with an extremely high affinity for human RANKL and a long half-life, which permits less frequent dosing. It was developed to treat patients with skeletal pathologies mediated by osteoclasts, such as bone metastasis, multiple myeloma, and cancer treatment-induced bone loss (CTIBM). On the basis of preclinical evidences, many clinical trials were conducted to investigate denosumab in metastatic bone disease. Specifically, we are waiting for the final results of the three ongoing clinical trials evaluating denosumab versus ZA in metastatic breast cancer, prostate cancer as well as advanced solid tumors and multiple myeloma. Specifically at ECOO 2009 Stopec et al. presented the first results regarding the Phase III study evaluating denosumab versus zoledronic acid (ZA) in breast cancer. They demonstrated that denosumab was superior to ZA and reduced the risk of a first on-study SRE by 18% (HR: 0.82, 95% CI: 0.71, 0.95; P value was less than 0.0001 for noninferiority and equal to 0.01 for superiority study) and of first and subsequent SRE by 23% on multiple event analysis (HR: 0.77; 95% CI: 0.66, 0.89; P = 0.001). Also the Phase III study evaluating denosumab versus ZA in other solid tumors plus multiple myeloma showed denosumab was not inferior compared with ZA for delaying the time to the first-on study SRE (HR: 0.84, 95% CI: 0.71, 0.98) (statistically significant for non inferiority p<0.0007). The time to first SRE and the time to first-and-subsequent SRE was also numerically greater but not statistically superior compared to ZA (HR: 0.90, 95% CI: 0.77, 1.04). At ASCO 2010 the results of the trial evaluating denosumab vs ZA in bone metastases from advanced cancer or multiple myeloma were presented. The time to first SRE or hypercalcemia of malignancy was significantly longer in the denosumab group (HR: 0.83 [95% CI: 0.71, 0.97], p = 0.02) as was time to first radiation to bone (HR: 0.78; 95% CI: 0.63, 0.97, p = 0.03). At ASCO 2010 the study evaluating denosumab compared with ZA for the treatment of bone metastases in patients with castration-resistant prostate cancer was presented. Denosumab significantly delayed the time to first on-study SRE compared with ZA (HR: 0.82; 95% CI: 0.71, 0.95; p = 0.008.) The median time to first on-study SRE was 20.7 mo denosumab vs. 17.1 mo ZA. Denosumab also significantly delayed the time to first and subsequent on-study SRE (multiple event analysis) (HR: 0.82; 95% CI: 0.71, 0.94; p = 0.004).

Endothelin pathway

The Endothelins (ET) are peptides containing 21 amino acids produced by a variety of normal cells, such as endothelial cells, vascular smooth muscle cells and various epithelial tissues. The endothelin family comprises four isoforms ET-1–4 (the most recently identified). Presently, ET-1 is the most clinically relevant isoform. The conversion to the active ET-1 form, after proteolytic cleavage of its inactive precursor, is the main regulatory step in controlling ET-1 levels within the body. Endothelins exert their effects by binding to two distinct G protein-coupled receptors,
achieved in this study, but an improvement was seen in overall placebo. The primary end point of time to progression was not to receive once-daily oral tablets of ZD4054 10 mg, or 15 mg, or for pain was carried out. Patients were randomized into 3 groups resistant prostate cancer who were pain free or mildly symptomatic ETAR antagonist ZD4054 in patients with metastatic hormone-

Phase 2 study to investigate the safety and efficacy of the specific metastatic prostate cancer, atrasentan (10 mg/day) did not reduce in a subsequent placebo-controlled phase III trial in men with symptomatic metastases will be randomized to receive zibotentan als.gov identifier NCT00617669) HRPC patients with confirmed related quality of life. ENTHUSE M1 (Study 0015, ClinicalTrials.gov identifier NCT00626548) is enrolling patients with HRPC with increasing PSA levels but no evidence of metastatic spread.

Patients will be accrued and randomized to zibotentan or placebo. Primary endpoints are overall survival, progression-free survival, defined as the time to appearance of metastases. Secondary endpoints include safety and tolerability, PSA levels and health-related quality of life. ENTHUSE M1 (Study 0014, ClinicalTrials.gov identifier NCT00554229), investigates zibotentan in HRPC patients with asymptomatic or mildly symptomatic metastases for whom chemotherapy is not yet appropriate randomized to zibotentan or placebo. The primary endpoint is overall survival; secondary endpoints include progression-free survival, safety and tolerability, skeletal events and bone metastases, PSA levels, and health-related quality of life. ENTHUSE M1c (Study 0033, ClinicalTrials.gov identifier NCT00617669) HRPC patients with confirmed symptomatic metastases will be randomized to receive zibotentan with docetaxel or docetaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, PSA levels, safety and tolerability, and the effect of treatment on skeletal events.

**Cathepsin K pathway**

Cathepsins are a class of globular lysosomal proteases that belong to the papain-like cysteine protease family. During the last 10 years Cathepsin K (CatK) has been the focus of increasing attention. It is expressed in a wide variety of tissues including the bone in which appears to be the most abundant and specific cysteine protease expressed by osteoclasts and osteoclast-like cells (giant multinucleated cells). Other cells within the bone milieu (e.g. osteoblasts and osteocytes) express cathepsin K although its role in these cells is not well known.

Cathepsin K represents the key enzyme responsible for osteoclastic bone resorption actively participating in the process of bone turnover. This cysteine protease plays a key role in bone matrix degradation and appears to be a limiting step in osteoclastic bone resorption.

The well established role of catk in bone resorption makes it an attractive therapeutic target in the treatment of those disorders involving bone loss, such as osteoporosis and bone metastasis.

Different cancers express cathepsin K including prostate and breast cancers both of which have a high tendency to metastasize to bone. Until now, a role for cathepsin K in bone metastasis has been mainly attributed to its ability to effectively degrade native collagen I, a process necessary for the expansion of tumour within the bone.

These observations suggest that inhibition of cathepsin K may disrupt two processes essential to the development of bone metastases: cancer cell invasion and osteoclast-mediated bone resorption. Experimental data on animal tumor models have shown inhibitors of cathepsin K effectively suppress bone resorption.

From this evidence, several small-molecule inhibitors of cathepsin K have been developed and will enter soon phase 1 experimental validation.

In vivo proof of concept study designed for treatment of osteolysis and tumor growth in metastatic bone disease, cathepsin K inhibitor (L-006235) showed to reduce the size of osteolytic lesions by 66% when administered 18 days after tumor cell inoculation and 61% when administrated at the same time as tumor cell inoculation.

Moreover, sequential treatment L006235 (30 and 100) plus zoledronic acid (12 ug/kg) demonstrated additive efficacy in terms of protection from osteolysis and tumor volume.

Due to its selectivity, Odanacatib is the only cathepsin k inhibitor in clinical development. A Phase II controlled study on women with breast cancer metastatic to bone randomized to receive daily administration of odanacatib (5 mg) or a single 4 mg IV dose of zoledronic acid showed bone remodeling markers reduction (urinary NTX) after 4 weeks treatment.

**SRC pathway**

The proto-oncogene Src (encoded by the c-src gene) is a non-receptor, membrane-associated tyrosine kinases that belongs to Src family kinases.

Src is widely express, the majority of cell types display low levels of it while some others such as mature osteoclasts express high levels of it.

Src displays multiple functions both in physiological and pathological processes such as cell proliferation, migration, differentiation, survival angiogenesis, tumorigenesis and inflammation. In osteoclasts, Src is activated following integrin binding after cells attach to bone matrix to start the resorptive process and also after RANKL binding to RANK. Src signaling is a key pathway during normal, healthy bone turnover and has also been shown to be essential for the normal organization of the osteoclasts cytoskeleton.

With regard to bone remodeling Src coordinates both osteoclast and osteoblast activities: it positively regulates osteoclasts survival and resoring activity, and conversely, Src
may negatively regulate osteoblast maturation through inhibition of runt-related transcription factor 2 (Runx2) regulated genes.27 Thus, Src kinase is essential for osteoclast activation and osteoblast inhibition. During tumorigenesis Src aberrantly activate certain physiological processes thereby supporting tumor growth, metastatization and tissue invasion. Moreover, an increased expression and activity of Src have been described in a wide variety of tumor types including prostate, colon and breast cancer.28 The Src role in patients with metastatic bone disease is of particular importance given its involvement in both bone turnover and bone metastases formation. An increased Src-mediated osteoclastic activity leads to an uncontrolled release of growth factors (such as TGF-β, IGF I, II, PDGF) into the bone microenvironment due to the enhanced bone resorption process. Evidence for the importance of Src in the formation of bone metastases comes from studies in mice showing how Src inhibition or disruption results in a diminished capacity of bone metastases development.

Increased Src activity is known to correlate with tumor progression, with the highest activity in metastatic tissue. Pre-clinical studies have demonstrated that decreased c-Src expression enhances osteoblast proliferation and bone formation.29 Different Src inhibitors have been developed by the pharmaceutical industry with several of them in advanced clinical trials.

Saracatinib (AZD0530) is an orally active small-molecular-weight inhibitor of c-Src and BCR-Abl. Its efficacy in bone resorption has been demonstrated in two phase I clinical trials.30 Dasatinib, saracatinib, and bosutinib are currently being investigated in early clinical trials in patients with prostate or breast cancer. Results have also been reported from a phase 1/2 study of dasatinib administered in combination with docetaxel in patients with progressive CRPC. Bone markers (uNTX, BAP) decrease, a PSA decline, and RECIST partial response was registered.31

In a phase 2 trial of saracatinib (175 mg daily) in patients with advanced CRPC, treatment was well tolerated and five patients had a slight reduction in PSA. However, bone effects were not reported.32 In a small study of patients with multiple myeloma, dasatinib had effects on markers of osteoclast but not osteoblast function.33 Several clinical trials are ongoing with SRC inhibitors to evaluate bone markers as a specified endpoint in addition to tumor responses, including the randomized phase 3 trial of dasatinib in combination with docetaxel (NCT00744497). Trials in breast cancer include: two randomized phase 2 studies of the aromatase inhibitors exemestane (NCT00767520) or letrozole (NCT00696072) administered with or without dasatinib; a randomized phase 2 study of fulvestrant (estrogen receptor antagonist) with or without dasatinib (NCT00566618); a phase 1/2 study of dasatinib in combination with zoledronic acid (NCT00566618); and a phase 2 of dasatinib administered either once or twice daily in patients with breast cancer and bone metastases (NCT00410813). Saracatinib effects on bone markers will be evaluated in a randomized phase 2 trial versus zoledronic acid in patients with prostate or breast cancer (NCT00558272) and a phase 2 study of patients with metastatic hormone receptor-negative or locally advanced unresectable breast cancer (NCT00559507). Randomized phase 2 trials of exemestane (NCT00793546) or letrozole (NCT00880009) with or without bosutinib are either planned or ongoing, respectively, although it is currently unclear if bone markers will be assessed.

Conclusion: Potential new targets and future perspective

In summary, a variety of novel targets in management of bone disease are underway in preclinical and clinical testing phases. The results from those in the advanced clinical phases are encouraging and underlined the need to design large randomised clinical trials to validate these results in the next future. Denosumab is the molecule which is in the most advanced development phase, presently being tested in Phase III trials. Further definition of the molecular and cellular pathways involved into bone metastasis biology is ongoing and it will likely lead to new and improved therapeutic strategies in bone metastasis. For example Notch is emerged as an important target in bone homeostasis. Mice knocked down for Notch lost the ability to suppress bone resorption. Targeting Notch pathway by gamma secretase inhibitors could represent in the next future a feasible therapeutic strategy.

Moreover, many new therapeutic targets in bone metastases, including TGF-β, Src, CXC4, GPNMB and EGF-family ligands are currently under pre clinical investigation.
Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major clinical impact in improving survival in bone metastatic patients and in preventing disease relapse in adjudant setting.

Acknowledgements

On behalf of Italian Society of Osteoncology.

Conflict of interests

All authors declare no conflict of interest.

References